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Abstract
Background. Extramedullary disease is an uncommon manifestation in multiple myeloma and can either accompany newly diagnosed disease or can develop with disease progression or relapse. We evaluated the impact of this disease feature on patient outcome in the context of novel agents.
Design and Methods.
We analyzed clinical and biological features of extramedullary disease in 936 patients with multiple myeloma enrolled in Total Therapy protocols, 240 patients in non-Total Therapy protocols, and 789 nonprotocol patients, all of whom had baseline PET scans to document extramedullary disease at diagnosis and its subsequent development at the time of disease progression or relapse.
Results. The most common sites for extramedullary disease at diagnosis were skin and soft tissue whereas liver involvement was the striking feature in extramedullary disease at disease relapse or progression. Regardless of therapy, extramedullary disease was associated with shorter progression-free and overall survival, as well presence of anemia, thrombocytopenia, elevated serum LDH, cytogenetic abnormalities, and high-risk features in 70-and 80-gene risk models in univariate analysis. Multivariate analysis with logistic regression revealed that this disease feature was more prevalent in patients with elevated centrosome index by gene expression profiling, as well as myeloma molecular subtypes that are more prone for relapse. These include MF subtype (also called "MAF" subtype, associated with over expression of MAF gene seen with chromosome translocation 14;16 or translocation 14;20, respectively) and PR subtype (also called "Proliferation" subtype, associated with overexpression of pro-proliferative genes).
Conclusions. These data show that extramedullary disease is more prevalent in genomically defined high risk multiple myeloma and is associated with a shorter progression free survival and overall survival, even in the era of novel agents.
All clinical trials included in the analyses were registered with www.clinicaltrials.gov (NCT00083551, NCT00083876, NCT00081939, NCT00572169, NCT00644228,NCT00002548,NCT00734877)
INTRODUCTION
Therapeutic advances over the last decade have nearly doubled the overall survival (OS) of patients with multiple myeloma due to availability of effective novel agents (1), over 50% when compared with patients in the pre-2000 era and will hopefully increase the number of newly diagnosed patients who are living over 10 years after treatment initiation (2) . The role of imaging techniques, such as PET scans and MRI, are emerging as prognostic tools that can predict response earlier compared with conventional response criteria (3, 4) .
However, as with other malignancies that have been successfully treated with increasingly effective regimens, marked extension of OS has also led to previously uncommon clinical presentations. In the case of MM, these include relapses at extramedullary sites, such as visceral organs, lymph nodes, and the central nervous system (mainly as meningeal myelomatosis) and secondary plasma-cell leukemia (SPCL).
In the case of extramedullary disease (EMD), it can either present at the time of initial diagnosis, as evidenced on baseline imaging studies such as PET and MRI, or at the time of disease relapse. It usually resembles a transformed malignant lymphoma both clinically and morphologically as well as in terms of laboratory features, such as high serum levels of lactate dehydrogenase (LDH).
In addition, the majority of patients presenting with EMD also present with highly complex CA and, most recently, high-risk GEP features (5-8). In a classic monoclonal immunoglobulin-secreting tumor, EMD may present as light chainsecretory, hypo-secretory, or altogether non-secretory disease as a sign of DOI: 10.3324/haematol.2012.065698 disease de-differentiation and transformation (9). In this setting, modern imaging tools, especially 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET), have become extremely helpful in documenting suspected EMD (10).
In our clinical practice, EMD is a rare primary disease manifestation;
rather, it appears to evolve with repeated relapses. Herein we have attempted to identify the clinical and biological risk factors that are associated with EMD in our MM patient population, and its impact on treatment outcomes. In addition, an independent, federally accredited investigator team had audited charts of more than 80% of patients for protocol eligibility, compliance with required tests and intended therapies, and for accuracy of toxicity and efficacy reporting. 6 We focused on 936 patients in TT protocols, 240 patients in non-TT protocols, and 789 non-protocol patients , (total N=1965) all of whom had baseline PET scans at initial presentation prior to therapy at MIRT to document primary EMD (EMD-1). We also documented which of these patients developed EMD (EMD-2) at the time of disease progression or relapse. Chi-square and
DESIGN AND METHODS
Our
Fisher's exact tests were used to compare baseline characteristics between protocols. Logistic regression was used for multivariate analyses to model associations between baseline covariates and EMD-1. The Kaplan and Meier method was used to calculate progression-free survival (PFS) and OS from the initial transplant at MIRT. The cumulative incidence of EMD was calculated as described by Gooley (10).
Gene expression profiling(GEP) was performed with the Affymetrix U133Plus2.0 microarray platform (Santa Clara, CA) using methods previously 
RESULTS
EMD-1 was documented in 2.41% of TT protocol patients, 4.35% of non-
TT protocol patients, and 4.50% of non-protocol patients. The incidence of EMD-2 in patients 5 years after autologous stem cell transplantation was documented in 3.43% of TT protocol patients, 5.2% of non-TT protocol patients, and 7.24%
non-protocol patients. The most common sites of EMD-1 included the chest wall, liver, lymph nodes, skin/soft tissue, and paraspinal area whereas EMD-2 showed a preponderance of liver involvement ( Table 1) .
Baseline patient characteristics were compared among EMD-1 patients and non-EMD patients using Fisher's exact or Chi-square tests, depending on group sizes. In univariate analysis, EMD-1 was significantly linked to GEPdefined risk, pre-transplant CA, low levels of hemoglobin, low platelet counts and, only marginally, to elevated LDH ( Table 2) In the absence of differences in CR frequency, the OS was shorter in EMD-1 than in non-EMD patients (31% vs. 59% after 5 years, p< 0.001; There is limited data on the true incidence and biology of EMD in MM.
Two previous publications reported the incidence of EMD-1 and EMD-2 to be 15% and 20%, respectively (5, 6). In a large study of 1003 consecutive MM patients (7), it was observed that EMD accounted for 13% of cases (7% EMD-1 and 6% EMD-2). in patients who had GEP-defined high-risk disease at baseline and baseline CA and was associated with a grave prognosis. Data published from the Mayo Clinic (13) has shown poor prognostic genetic markers to be associated with centrosome amplification. We found centrosome amplification was associated with higher incidence of EMD. While uncommon at disease progression or relapse, EMD-2 represents a common terminal pathway in MM and is linked with increased hepatic preponderance.
Based on the published literature and the date presented herein, EMD is a poor prognostic marker in both newly diagnosed and relapsed MM patients, therefore representing a therapeutic challenge even in the era of novel agents.
The authors have collected gene expression profiling data from both EMD-1 and EMD-2 sites. Additional studies comparing baseline GEP in EMD and non-EMD patients and comparing baseline GEP and EMD-GEP in patients who develop EMD are underway to understand the distinctive biology of this subset of patients. As the field moves towards more individualized therapies even within a specific cancer, the GEP studies may help in identifying EMD-unique gene(s)
that may be amenable to targeted agent development.
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